Anticancer drugs plus cytokines: immunodulation based therapies of mouse tumors (Q34117992)

31 July 2017

1 reference

title

Anticancer drugs plus cytokines: immunodulation based therapies of mouse tumors (English)

1 reference

31 July 2017

Mihich E

1

1 reference

PubMed ID

11137614

31 July 2017

Ehrke MJ

series ordinal

2

1 reference

31 July 2017

1 December 2000

1 reference

International Journal of Immunopharmacology

31 July 2017

1 reference

31 July 2017

22

1 reference

31 July 2017

12

1 reference

31 July 2017

1077-1081

1 reference

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900072-2

7 January 2021

Immunotherapy of cancer with dendritic-cell-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900072-2

7 January 2021

Historical overview of biologic response modifiers

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900072-2

7 January 2021

Taxol, a microtubule-stabilizing antineoplastic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900072-2

7 January 2021

Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900072-2

7 January 2021

Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900072-2

7 January 2021

Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900072-2

7 January 2021

Protective specific immunity induced by doxorubicin plus TNF-alpha combination treatment of EL4 lymphoma-bearing C57BL/6 mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900072-2

7 January 2021

Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0192-0561%2800%2900072-2

7 January 2021

10.1016/S0192-0561(00)00072-2

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11137614